Five-year Outcomes with First-Line Nivolumab Plus Ipilimumab with 2 Cycles of Chemotherapy Versus 4 Cycles of Chemotherapy Alone in Patients with Metastatic Non-Small Cell Lung Cancer in the Randomized CheckMate 9LA Trial
EUROPEAN JOURNAL OF CANCER（2024）
Key words
Chemotherapy drug,Cancer,Immunotherapy,Ipilimumab,Nivolumab,Non-small-cell lung carcinoma
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined